JP2018512876A - saRNA組成物および使用方法 - Google Patents

saRNA組成物および使用方法 Download PDF

Info

Publication number
JP2018512876A
JP2018512876A JP2017555233A JP2017555233A JP2018512876A JP 2018512876 A JP2018512876 A JP 2018512876A JP 2017555233 A JP2017555233 A JP 2017555233A JP 2017555233 A JP2017555233 A JP 2017555233A JP 2018512876 A JP2018512876 A JP 2018512876A
Authority
JP
Japan
Prior art keywords
sarna
strand
target
sequence
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017555233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512876A5 (https=
JP2018512876A6 (ja
Inventor
サトロム、ポール
バッケン ストブナー、エンドレ
バッケン ストブナー、エンドレ
Original Assignee
ミナ セラピューティクス リミテッド
ミナ セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミナ セラピューティクス リミテッド, ミナ セラピューティクス リミテッド filed Critical ミナ セラピューティクス リミテッド
Publication of JP2018512876A publication Critical patent/JP2018512876A/ja
Publication of JP2018512876A6 publication Critical patent/JP2018512876A6/ja
Publication of JP2018512876A5 publication Critical patent/JP2018512876A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
JP2017555233A 2015-04-22 2016-04-21 saRNA組成物および使用方法 Pending JP2018512876A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201562150893P 2015-04-22 2015-04-22
US201562150892P 2015-04-22 2015-04-22
US201562150895P 2015-04-22 2015-04-22
US201562150904P 2015-04-22 2015-04-22
US201562150908P 2015-04-22 2015-04-22
US201562150900P 2015-04-22 2015-04-22
US201562150897P 2015-04-22 2015-04-22
US62/150,892 2015-04-22
US62/150,893 2015-04-22
US62/150,904 2015-04-22
US62/150,897 2015-04-22
US62/150,895 2015-04-22
US62/150,908 2015-04-22
US62/150,900 2015-04-22
PCT/GB2016/051116 WO2016170348A2 (en) 2015-04-22 2016-04-21 Sarna compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020162713A Division JP2021035360A (ja) 2015-04-22 2020-08-19 saRNA組成物および使用方法

Publications (3)

Publication Number Publication Date
JP2018512876A true JP2018512876A (ja) 2018-05-24
JP2018512876A6 JP2018512876A6 (ja) 2018-10-11
JP2018512876A5 JP2018512876A5 (https=) 2019-05-09

Family

ID=56363867

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017555233A Pending JP2018512876A (ja) 2015-04-22 2016-04-21 saRNA組成物および使用方法
JP2020162713A Pending JP2021035360A (ja) 2015-04-22 2020-08-19 saRNA組成物および使用方法
JP2022212928A Pending JP2023040138A (ja) 2015-04-22 2022-12-19 saRNA組成物および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020162713A Pending JP2021035360A (ja) 2015-04-22 2020-08-19 saRNA組成物および使用方法
JP2022212928A Pending JP2023040138A (ja) 2015-04-22 2022-12-19 saRNA組成物および使用方法

Country Status (4)

Country Link
US (2) US20180305689A1 (https=)
EP (1) EP3286318A2 (https=)
JP (3) JP2018512876A (https=)
WO (1) WO2016170348A2 (https=)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108753967A (zh) * 2018-06-08 2018-11-06 复旦大学附属中山医院 一种用于肝癌检测的基因集及其panel检测设计方法
CN109097466A (zh) * 2018-09-21 2018-12-28 王赞鑫 与主动脉夹层疾病相关的snp位点及其应用
CN109207585A (zh) * 2018-11-01 2019-01-15 中国人民解放军第Oo医院 免疫性血小板减少症lncRNA标志物及试剂盒和应用
CN110184358A (zh) * 2019-06-25 2019-08-30 台州市立医院 甲状腺癌早期诊断用的oit3基因及其应用
KR20210089178A (ko) * 2018-10-30 2021-07-15 소마로직, 인크. 샘플 품질 평가 방법
JP2022517803A (ja) * 2019-01-17 2022-03-10 エフ.ホフマン-ラ ロシュ アーゲー E3ユビキチンリガーゼ(ube3a)のタンパク質標的
JP2022552940A (ja) * 2019-09-20 2022-12-21 ラクティゲン セラピューティクス 血小板減少症を治療するための核酸分子及びその応用
JP2023514292A (ja) * 2020-02-14 2023-04-05 カーディオミックス エス.アール.エル. ブルガダ症候群の診断のためのバイオマーカーセット
JP2023550697A (ja) * 2020-10-30 2023-12-05 ▲復▼旦大学 免疫応答調節または抗腫瘍のための薬剤の調製におけるitpripl1のモジュレーターとしての使用
WO2024005158A1 (ja) * 2022-06-30 2024-01-04 武田薬品工業株式会社 オリゴヌクレオチド
JP2024500823A (ja) * 2020-12-23 2024-01-10 イーライ リリー アンド カンパニー Rna治療薬及びその使用方法
JP2024543933A (ja) * 2022-01-14 2024-11-26 タスリー・ステム・セル・バイオロジー・ラボラトリー・タスリー・グループ・リミテッド 間葉系間質細胞品質評価方法

Families Citing this family (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
WO2016130600A2 (en) 2015-02-09 2016-08-18 Duke University Compositions and methods for epigenome editing
KR102787119B1 (ko) 2015-11-30 2025-03-27 듀크 유니버시티 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
EP3390669B1 (en) * 2015-12-20 2024-07-31 The National Institute for Biotechnology in the Negev, Ltd. Biomarkers of chronic lymphocytic leukemia and use thereof
WO2017112921A1 (en) * 2015-12-24 2017-06-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for characterizing sepsis
US11492386B2 (en) * 2016-02-01 2022-11-08 Eli Lilly And Company Parathyroid hormone-anti-RANKL antibody fusion compounds
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
EP3458466B1 (en) 2016-05-20 2024-08-07 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes
GB201611738D0 (en) 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
JP7490211B2 (ja) 2016-07-19 2024-05-27 デューク ユニバーシティ Cpf1に基づくゲノム編集の治療適用
UY37376A (es) * 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
EP3327134A1 (en) * 2016-11-28 2018-05-30 Carsten Korth Method and biomarkers for in vitro diagnosis of mental disorders
CN106834288B (zh) * 2016-12-16 2020-08-21 南京医科大学 一种长非编码rna及其在诊断/治疗胃癌中的应用
MX2019008199A (es) 2017-01-06 2019-11-25 Avidity Biosciences Llc Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
CN106929508B (zh) * 2017-02-17 2020-08-21 张灏 一种激活PTPRO基因表达的saRNA及其转运载体
US11306311B2 (en) * 2017-06-08 2022-04-19 Chandrasekhar Kanduri Long non-coding RNA in cancer
GB201709866D0 (en) * 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
US10392616B2 (en) * 2017-06-30 2019-08-27 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
WO2019051312A1 (en) * 2017-09-07 2019-03-14 University Of Massachusetts THERAPY AGAINST SELENIUM CANCER
US20200208152A1 (en) 2017-09-08 2020-07-02 Mina Therapeutics Limited Stabilized sarna compositions and methods of use
US20210130776A1 (en) * 2017-09-29 2021-05-06 The Broad Institute, Inc. Methods and compositions for modulating suppression of lymphocyte activity
JP7277460B2 (ja) 2017-11-30 2023-05-19 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ 乳癌の検出
KR102723989B1 (ko) * 2017-12-01 2024-11-01 더 텍사스 에이 & 엠 유니버시티 시스템 엔젤만 증후군 안티센스 치료
CN107988223B (zh) * 2017-12-06 2021-08-13 张灏 一种激活PTPRO基因表达的saRNA及其在肿瘤干细胞治疗中的应用
AU2018378812B2 (en) 2017-12-06 2025-05-22 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
EP3720508A4 (en) * 2017-12-08 2021-09-01 University of Connecticut COMPOSITIONS AND METHODS FOR TREATMENT OF GENOMIC FOOTPRINT DISORDERS
CN108130368B (zh) * 2017-12-21 2021-12-14 中国医学科学院北京协和医院 lncRNA在制备诊断或预示青少年特发性脊柱侧凸产品中的应用
CN108085389B (zh) * 2017-12-29 2020-06-09 青岛泱深生物医药有限公司 一种与乳腺癌相关的lncRNA及其应用
CN107937550B (zh) * 2018-01-08 2020-06-02 青岛泱深生物医药有限公司 一种与乳腺癌发生发展相关的生物标志物及其应用
EP3740580A4 (en) 2018-01-19 2021-10-20 Duke University GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS
EP3735248A4 (en) * 2018-02-09 2021-11-17 Empirico Inc. PROCESS FOR INHIBITED OR ELIMINATING EOSINOPHILIC DISEASES OF THE RESPIRATORY TRACT AND ASSOCIATED CONDITIONS
PH12020551219A1 (en) 2018-02-14 2021-04-19 Deep Genomics Incorporated Oligonucleotide therapy for wilson disease
MA51869A (fr) * 2018-02-16 2020-12-23 Bayer Healthcare Llc Compositions et méthodes pour l'édition génique par ciblage du fibrinogène-alpha
MX2020008581A (es) 2018-02-21 2020-09-21 Bristol Myers Squibb Co Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos.
CN108192973B (zh) * 2018-03-02 2021-06-04 中南大学湘雅医院 长链非编码rna linc00559作为生物标志物在制备肺腺癌预后检测制剂中的应用
CN108192974B (zh) * 2018-03-02 2021-11-05 中南大学湘雅医院 长链非编码rna linc00842作为生物标志物在制备肺腺癌预后检测制剂中的应用
CN108192976B (zh) * 2018-03-02 2021-06-04 中南大学湘雅医院 长链非编码rna linc00336作为生物标志物在制备肺鳞癌预后检测制剂中的应用
CN108192975B (zh) * 2018-03-02 2021-06-04 中南大学湘雅医院 长链非编码rna linc00559作为生物标志物在制备肺鳞癌预后检测制剂中的应用
US20210332366A1 (en) * 2018-04-10 2021-10-28 Ractigen Therapeutics Novel Small Activating RNA
EP3775211B1 (en) * 2018-04-12 2023-04-05 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
CN110468200B (zh) * 2018-05-10 2023-02-28 复旦大学附属肿瘤医院 一种用于癌症预后的多基因检测试剂盒
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
GB2589224A (en) * 2018-06-01 2021-05-26 Childrens Nat Medical Ct Compositions and methods for treating and preventing muscular disorders and dystrophies, steroid side effects, and inflammation
CN108424969B (zh) * 2018-06-06 2022-07-15 深圳市颐康生物科技有限公司 一种生物标志物、诊断或预估死亡风险的方法
EP3813844A1 (en) * 2018-06-28 2021-05-05 United Kingdom Research and Innovation Treatment of cardiomyopathy through modulation of hypoxia-induced erna activity
JP7571005B2 (ja) * 2018-08-04 2024-10-22 インペリアル・カレッジ・イノベーションズ・リミテッド 川崎病を患う対象を特定する方法
CN109097464B (zh) * 2018-09-19 2021-12-14 中国医学科学院阜外医院深圳医院(深圳市孙逸仙心血管医院) Cfap43基因的snp位点的应用
CN109097465B (zh) * 2018-09-19 2021-06-08 蒲佐 Clip3基因的snp位点的应用
US12097239B2 (en) 2018-09-21 2024-09-24 President And Fellows Of Harvard College Methods and compositions for treating diabetes, and methods for enriching MRNA coding for secreted proteins
IL281470B2 (en) 2018-09-28 2025-08-01 Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
CN109182503B (zh) * 2018-09-28 2021-09-28 新乡医学院 动脉粥样硬化分子标志物及其应用
CN111020029B (zh) * 2018-10-10 2023-09-29 江苏普瑞悉恩生物科技有限公司 实时荧光定量pcr检测pd-l1基因表达量的方法、引物及试剂盒
US20210383924A1 (en) * 2018-10-25 2021-12-09 Quadrant Biosciences Inc. Methods and machine learning for disease diagnosis
US20210395738A1 (en) 2018-11-08 2021-12-23 Greenlight Biosciences, Inc. Control of insect infestation
CN109207598A (zh) * 2018-11-09 2019-01-15 汕头大学医学院附属肿瘤医院 一种长链非编码rna在制备食管癌诊断试剂或治疗药物中的应用
CA3119749A1 (en) * 2018-11-15 2020-05-22 Ampel Biosolutions, Llc Machine learning disease prediction and treatment prioritization
WO2020117706A1 (en) 2018-12-03 2020-06-11 Triplet Therapeutics, Inc. Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
CN109355391A (zh) * 2018-12-05 2019-02-19 山东省千佛山医院 Linc01876作为诊断肝癌的分子标志物的应用
CN110093348B (zh) * 2018-12-05 2022-11-29 西北工业大学 增强小鼠NPFFR2基因表达的shRNA
WO2020117840A2 (en) * 2018-12-05 2020-06-11 Empirico Inc. Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions
CN113227375A (zh) 2018-12-20 2021-08-06 原住民股份有限公司 合成的微小rna模拟物
IL312067B2 (en) 2018-12-21 2025-08-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and uses thereof
PE20212248A1 (es) * 2018-12-29 2021-11-24 Ractigen Therapeutics Molecula oligomerica de acido nucleico y uso de esta
CN109813912B (zh) * 2019-01-04 2021-12-28 深圳大学 一组血清差异蛋白组合在制备用于检测孤独症的试剂中的应用
CN109837336B (zh) * 2019-01-09 2022-07-19 中国人民解放军军事科学院军事医学研究院 辐射敏感基因标记物及在鉴别高let射线辐射中的应用
CN109652532A (zh) * 2019-01-11 2019-04-19 中国人民解放军总医院 一种检测心血管系统用药的标志物
WO2020150606A1 (en) * 2019-01-18 2020-07-23 The General Hospital Corporation Methods and compositions for modulating immune dysregulation
KR102162847B1 (ko) * 2019-01-23 2020-10-07 차의과학대학교 산학협력단 요로결석 진단을 위한 분석방법 및 키트
KR20210131322A (ko) * 2019-01-24 2021-11-02 락티젠 세러퓨틱스 피부 보호용 올리고머 핵산
JP2022529562A (ja) * 2019-01-30 2022-06-23 ラクティゲン セラピューティクス オリゴヌクレオチド分子及び腫瘍治療におけるその応用
US12569517B2 (en) 2019-02-07 2026-03-10 Direct Biologics, Llc Method for treating osteoarthritis with mesenchymal stem cell exosomes
WO2020172338A1 (en) * 2019-02-19 2020-08-27 Whitehead Institute For Biomedical Research Methods and agents for modulating mitochondrial nad levels
JP7224690B2 (ja) * 2019-03-07 2023-02-20 レチ マーク カンパニー リミテッド 糖尿病網膜症の診断用複合マーカーおよびその用途
US12595479B2 (en) * 2019-03-20 2026-04-07 President And Fellows Of Harvard College Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases
KR20200113556A (ko) * 2019-03-25 2020-10-07 황인후 St8sia1를 이용한 당뇨병의 예방 또는 치료용 조성물과 당뇨병 치료제 스크리닝 방법
EP3947735A4 (en) * 2019-03-25 2022-12-28 The Board Of Trustees Of The Leland Stanford Junior University SIGNATURE FOR DIAGNOSIS OF BACTERIAL VS VIRAL INFECTIONS
CN109880828B (zh) * 2019-03-26 2021-02-05 河南师范大学 干扰Mroh7基因表达的siRNA及其应用、干扰方法与药物
EP3947700A4 (en) 2019-04-01 2023-01-04 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
EP3956448A4 (en) * 2019-04-18 2022-10-19 University of Massachusetts AIM2 INHIBITORS AND USES THEREOF
WO2020219820A1 (en) 2019-04-25 2020-10-29 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
CN111849968A (zh) * 2019-04-30 2020-10-30 中美瑞康核酸技术(南通)研究院有限公司 寡核苷酸分子及其在急性间歇性卟啉症治疗中的应用
EP3965777A4 (en) * 2019-05-06 2024-08-07 The Children's Hospital of Philadelphia MICRORNA SITE-BLOCKING OLIGONUCLEOTIDES FOR THE TREATMENT OF EPILEPTIC ENCEPHALOPATHY AND NEURODEVELOPMENTAL DISORDERS
WO2020227713A1 (en) * 2019-05-09 2020-11-12 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of leukodystrophy and whole animal and cellular models for the identifying efficacious agents for treatment of the same
CN110079601B (zh) * 2019-05-23 2022-04-19 青岛市中心医院 放射性相关疾病诊疗标志物及其应用
CN110106180B (zh) * 2019-05-29 2020-10-16 中国医科大学附属盛京医院 一种lncRNA分子及其在胶质瘤治疗/预后评估中的应用
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
CN110117659B (zh) * 2019-06-18 2022-10-11 上海奕谱生物科技有限公司 一种新型的肿瘤标记物stamp-ep10及其应用
US20230159920A1 (en) * 2019-06-26 2023-05-25 Fred Hutchinson Cancer Research Center Methods and compositions comprising brd9 activating therapies for treating cancers and related disorders
US12213995B2 (en) 2019-07-18 2025-02-04 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
CN110577988B (zh) * 2019-07-19 2022-12-20 南方医科大学 胎儿生长受限的预测模型
CN110456060B (zh) * 2019-07-31 2022-09-09 四川大学华西医院 Efcab13自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
EP4013870A1 (en) * 2019-08-13 2022-06-22 Alnylam Pharmaceuticals, Inc. Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof
US20220281911A1 (en) 2019-08-19 2022-09-08 Mina Therapeutics Limited Oligonucleotide conjugate compositions and methods of use
CN110541027A (zh) * 2019-08-21 2019-12-06 昆明医科大学第一附属医院 lncRNA HIF1A-AS1抗深静脉血栓的应用
CN112444627B (zh) * 2019-09-05 2022-03-29 四川大学华西医院 一种高危胸痛筛查试剂盒
EP4055175A4 (en) * 2019-11-04 2023-11-29 Decibel Therapeutics, Inc. Cochlear inner hair cell promoters and uses thereof
JP2023501352A (ja) * 2019-11-08 2023-01-18 アイオーニス ファーマシューティカルズ, インコーポレーテッド Spdef発現を低減するための化合物及び方法
CN110876752B (zh) * 2019-11-18 2021-04-30 暨南大学 长链非编码rna nron功能基序在制备抑制骨吸收及防治骨质疏松药物中的应用
WO2021113805A1 (en) * 2019-12-05 2021-06-10 The General Hospital Corporation Multi-biomarker prediction models for multiple infection episodes following blunt trauma
CN111197073A (zh) * 2019-12-19 2020-05-26 武汉艾米森生命科技有限公司 从粪便中提取dna样本的方法和结直肠癌相关基因的甲基化检测方法
CN112795579B (zh) * 2019-12-25 2022-03-18 四川省人民医院 克山病基因筛查试剂盒
CN113092774B (zh) * 2020-01-09 2022-08-19 中国科学院生物物理研究所 mtEF4蛋白作为毛发生长和脱发的生物标志物的用途
CN111118154B (zh) * 2020-01-16 2022-10-18 华南协同创新研究院 Linc01272在制备肿瘤检测试剂和/或治疗药物中的应用
CN113134010B (zh) * 2020-01-20 2023-09-01 上海市生物医药技术研究院 一种靶向雌激素受体α的微小RNA及其抗肿瘤用途
WO2021151059A1 (en) * 2020-01-24 2021-07-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Compounds and methods for treating or reducing pruritus
CN111214482B (zh) * 2020-02-21 2022-11-11 东莞市第八人民医院(东莞市儿童医院) 一种靶向linc00467基因的siRNA在白血病耐药性中的应用
CN111254193A (zh) * 2020-02-27 2020-06-09 上海交通大学 Dna甲基化标志物pcyt1a在制备诊断pcos试剂盒中的应用
CN111440867B (zh) * 2020-03-06 2020-12-22 河北医科大学第二医院 生物标志物在肝癌诊断和治疗中的应用
CN111394351B (zh) * 2020-03-18 2023-11-07 济南爱新卓尔医学检验有限公司 一种抑制DICER1-AS1表达的siRNA及其应用
WO2021188390A1 (en) 2020-03-19 2021-09-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
SI4126066T1 (sl) 2020-03-27 2026-04-30 Avidity Biosciences, Inc. Sestavki in postopki zdravljenja mišične distrofije
KR20230023612A (ko) 2020-04-02 2023-02-17 마이레큘, 인크. 조작된 올리고뉴클레오티드를 사용한 표적화된 억제
CN111424091B (zh) * 2020-04-20 2022-02-08 中国医学科学院北京协和医院 一组鉴别诊断甲状腺滤泡性肿瘤良恶性的标志物及其应用
KR20230004709A (ko) 2020-04-22 2023-01-06 다이렉트 바이오로직스 엘엘씨 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물
CN111458510B (zh) * 2020-04-30 2020-10-30 郑州大学第一附属医院 一组早期食管癌和高危人群筛查标志物及相关联检卡
WO2021231713A2 (en) 2020-05-14 2021-11-18 Ampel Biosolutions, Llc Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus
EP4153995A4 (en) * 2020-05-19 2024-10-23 Falcon Bioscience, LLC DETECTION AND TREATMENT OF CONDITIONS CHARACTERIZED BY PERFUSION ENGAGEMENT
CN111562394B (zh) * 2020-06-02 2021-07-02 西安交通大学医学院第一附属医院 热休克因子2结合蛋白在肝脏缺血再灌注损伤、药物性肝损伤中的应用
KR20230022167A (ko) * 2020-06-10 2023-02-14 락티젠 세러퓨틱스 Mitf 유전자를 표적으로 하는 핵산 분자 및 이의 사용
EP4168549A4 (en) * 2020-06-19 2024-10-09 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR PMP22 MODULATION
CN111718956B (zh) * 2020-06-30 2022-11-04 山东农业大学 一种鸡源trim25基因重组荧光表达质粒的制备方法和应用
CN111593127A (zh) * 2020-06-30 2020-08-28 北京泱深生物信息技术有限公司 与喉鳞癌密切相关的非编码rna
CN111910000B (zh) * 2020-07-02 2022-07-01 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 一种预测鼻咽癌预后的肿瘤微环境成分标志物组合及系统
CN111778562A (zh) * 2020-07-08 2020-10-16 复旦大学附属华山医院 一种用于获取颅颈动脉夹层致病基因突变相关信息的dna文库及应用
CN112063707B (zh) * 2020-07-09 2022-04-22 浙江大学 长链非编码rna loc102724238在诊断和治疗原发性翼状胬肉中的应用
CN113930423B (zh) * 2020-07-14 2024-05-10 北京大学 保护心肌细胞免受应激损伤的saRNA及其应用
WO2022015998A1 (en) * 2020-07-15 2022-01-20 University Of Connecticut Gene panels and methods of use thereof for screening and diagnosis of congenital heart defects and diseases
CN111733249B (zh) * 2020-07-21 2020-12-11 北京泱深生物信息技术有限公司 喉癌发生发展相关分子标志物
WO2022022617A1 (en) * 2020-07-31 2022-02-03 Ractigen Therapeutics Combinatory treatment of sma with sarna and mrna modulators
CN116390759A (zh) * 2020-08-03 2023-07-04 卡斯玛治疗公司 Tfeb激活和溶酶体生物发生的方法以及用于其的组合物
WO2022035984A1 (en) * 2020-08-12 2022-02-17 Skyhawk Therapeutics, Inc. Antisense oligonucleotides for treatment of conditions and diseases related to trem2
CN112094896B (zh) * 2020-08-27 2024-02-09 上海市公共卫生临床中心 活动性结核病诊断标志物、试剂盒及其应用
CA3189065A1 (en) 2020-09-11 2022-03-17 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
US20230372542A1 (en) * 2020-09-30 2023-11-23 The Regents Of The University Of California Composition and methods for modulating tcf4 gene expession and treating pitt hopkins syndrome
BR112023006305A2 (pt) 2020-10-09 2023-05-09 Tenaya Therapeutics Inc Métodos e composições de terapia gênica com placofilina-2
CN112143813B (zh) * 2020-10-28 2021-06-29 镇江市第一人民医院 Prr34-as1作为新型分子标志物及其定量检测方法和应用
CN112575076A (zh) * 2020-11-02 2021-03-30 深圳恒生医院 一种用于检测和评估早期自然流产的LncRNA标记物及应用其的产品
EP4244360A4 (en) * 2020-11-16 2025-05-07 Beijing SoloBio Genetechnology Company Ltd. Recombinant adeno-associated viruses with enhanced liver tropism and uses thereof
CN112251513B (zh) * 2020-11-26 2023-02-17 中国人民解放军总医院第一医学中心 一种食管癌和/或胃癌分子标志物Lnc5q31.1、引物、试剂盒及应用
CN112553199A (zh) * 2020-11-30 2021-03-26 深圳市人民医院 一种snhg17-KO基因敲除小鼠模型的构建方法和应用
CN112553333B (zh) * 2020-12-08 2022-03-08 南方医科大学深圳医院 miR-1207及其靶基因在检测喉鳞癌中的应用
CN112661826B (zh) * 2020-12-25 2022-03-29 中山大学 小肽ERpeptide及其在急性髓系白血病中的应用
CN112641797B (zh) * 2020-12-30 2021-12-17 温州医科大学 抑制结直肠癌生长、转移的靶标与诊断标志物及其应用
EP4277999A4 (en) * 2021-01-14 2024-12-18 Loma Linda University METHODS FOR EVALUATION OF EARLY STAGE ORAL SQUAMOUS CELL CARCINOMA
CN114958844A (zh) * 2021-01-27 2022-08-30 青岛市妇女儿童医院 一种基因调节剂在抑制口腔癌中的应用
CN112941076B (zh) * 2021-02-05 2023-07-07 中国药科大学 FXR靶向的saRNA及其应用
CN112961914B (zh) * 2021-02-07 2022-08-30 安徽省立医院(中国科学技术大学附属第一医院) miR-3074-5p作为类风湿关节炎标志物的应用及其试剂盒
CN112725471B (zh) * 2021-03-12 2022-09-16 中国大熊猫保护研究中心 野化培训大熊猫免疫适应的分子标记评估方法
TW202305133A (zh) * 2021-03-26 2023-02-01 英商米納治療有限公司 Tmem173 sarna組合物及其使用方法
WO2022212208A1 (en) * 2021-03-29 2022-10-06 University Of Massachusetts Oligonucleotides for syngr-3 modulation
WO2022215066A1 (en) * 2021-04-05 2022-10-13 Itayandbiond Ltd Small activating rna increasing shank expression and method of treating intellectual disabilities and associated comorbidities associated with shank haploinsufficiency
CA3214688A1 (en) 2021-04-08 2022-10-13 Andrzej KROLEWSKI Methods of diagnosing and predicting renal decline
WO2022214635A1 (en) * 2021-04-08 2022-10-13 Stichting Vu Nucleic acid molecules for compensation of stxbp1 haploinsufficiency and their use in the treatment of stxbp1-related disorders
US20240218454A1 (en) * 2021-04-22 2024-07-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Diagnostic to support clinical trial matching and exploratory biomarker analyses in cancer patients
WO2022226267A1 (en) * 2021-04-23 2022-10-27 Alnylam Pharmaceuticals, Inc. iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN
CN112921098B (zh) * 2021-04-27 2023-05-05 深圳市人民医院 一种用于三阴性乳腺癌检测的标志物及其检测试剂和应用
CN113151471B (zh) * 2021-04-28 2022-08-12 复旦大学附属中山医院 用于检测肺腺癌kras突变的基因组合物、试剂盒和方法
WO2022245734A2 (en) * 2021-05-17 2022-11-24 Corlieve Therapeutics Methods and compositions for treating epilepsy
CN113234834A (zh) * 2021-07-09 2021-08-10 北京泱深生物信息技术有限公司 一组用于胰腺癌预后的基因及其应用
CN113430273B (zh) * 2021-08-17 2022-05-27 广州齐凯生物科技有限公司 长链非编码rna linc01565在急性髓系白血病预后中的应用
CN113925975B (zh) * 2021-08-31 2024-05-28 杭州师范大学 p53及UTX信使RNA纳米粒的制备方法及该信使RNA的应用
CN118265544A (zh) 2021-09-16 2024-06-28 艾维迪提生物科学公司 治疗面肩肱型肌营养不良的组合物和方法
CA3230433A1 (en) * 2021-09-16 2023-03-23 Barbara MURPHY Methods for treating and diagnosing risk of renal allograft fibrosis and rejection
WO2023064604A1 (en) * 2021-10-14 2023-04-20 New York Stem Cell Foundation, Inc. Modified cells and methods of use thereof
KR102711436B1 (ko) * 2021-10-26 2024-09-26 사회복지법인 삼성생명공익재단 대장암의 치료 및 전이 억제용 조성물 및 이의 용도
EP4422752A1 (en) * 2021-10-28 2024-09-04 Baylor College of Medicine Targeting neuronal sirpa for treatment and prevention of neurological disorders
WO2023081080A1 (en) * 2021-11-05 2023-05-11 The Johns Hopkins University Use of biomarkers in diagnosing and treating lupus nephritis
CN114134147B (zh) * 2021-11-16 2023-11-14 山东大学 一种调控fzd9的非编码rna及其应用
CN114214322A (zh) * 2021-11-23 2022-03-22 中国辐射防护研究院 LincR-0003及其作为辐射损伤早期诊断的分子标志物的用途
WO2023111337A1 (en) * 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Antisense oligonucleotide
EP4453209A1 (en) * 2021-12-20 2024-10-30 Freie Universität Berlin Methods and agents for increasing rbm3 expression
CN114196675A (zh) * 2021-12-24 2022-03-18 复旦大学附属肿瘤医院 靶向linc00624的反义寡核苷酸及其在乳腺癌治疗中的应用
CN114288315B (zh) * 2022-01-13 2022-08-16 暨南大学附属第一医院(广州华侨医院) 一种包含ccp110抑制剂的药物组合物及其应用
CN115247176B (zh) * 2022-01-17 2023-06-20 郑州大学第一附属医院 一种长链非编码rna及其应用
CN114540500A (zh) * 2022-03-21 2022-05-27 深圳市陆为生物技术有限公司 评价乳腺癌患者整体生存的产品
KR20240165951A (ko) * 2022-03-23 2024-11-25 피와이씨 테라퓨틱스 리미티드 녹내장 치료 방법
CN114774445B (zh) * 2022-03-29 2024-01-02 中国人民解放军西部战区总医院 一种dynlt5基因在动脉粥样斑及组织修复中的应用
US20230313191A1 (en) * 2022-03-29 2023-10-05 Direct Biologics Llc Rna comprising secretomes and methods of their use
WO2023191957A1 (en) * 2022-03-30 2023-10-05 Mirimus, Inc. Compositions and methods of generating novel amirna
CN114574493A (zh) * 2022-04-02 2022-06-03 中国科学院遗传与发育生物学研究所 一种编辑绵羊SOCS2基因的sgRNA组合、扩增用引物和应用
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
AU2023250231A1 (en) * 2022-04-08 2024-10-31 Scineuro Therapeutics Inc. Oligonucleotide for reducing the expression of leucine-rich repeat kinase 2 (lrrk2) and its use for preventing and/or treating human diseases
WO2023201276A2 (en) * 2022-04-12 2023-10-19 Orthobio Therapeutics, Inc. Lipid nanoparticles for gene editing systems
IT202200011546A1 (it) * 2022-06-01 2022-09-01 Univ Degli Studi Di Trento Sequenze di RNA non codificanti in grado di aumentare l'espressione delle proteine CHD8 e CHD2
CN114959041B (zh) * 2022-06-19 2023-08-22 瓯江实验室 抑制结直肠癌增殖转移的新靶标与诊断标志物及其应用
CN119654412A (zh) * 2022-06-27 2025-03-18 中美瑞康核酸技术(南通)研究院有限公司 激活补体因子h表达的寡核苷酸调节剂
WO2024006994A2 (en) * 2022-07-01 2024-01-04 The University Of Chicago Compositions and methods for the treatment of cancer by targeting the brca1 pseudogene 1 (brca1p1)
TW202403054A (zh) * 2022-07-04 2024-01-16 大陸商江蘇鵾遠生物科技股份有限公司 癌症特異性甲基化標誌物及其應用
CN115725587B (zh) * 2022-09-14 2023-07-18 中国人民解放军军事科学院军事医学研究院 一组特异性识别辐射敏感蛋白tp53i3的寡核苷酸适配体及试剂盒和检测方法
CN116103287B (zh) * 2022-09-19 2025-02-14 南通市肿瘤医院 一种抑制GRWD1基因的siRNA分子及其应用
CN116121247B (zh) * 2022-09-26 2025-11-11 青岛大学 促进ABCG2基因表达的saRNA及其应用
EP4599061A1 (en) * 2022-10-06 2025-08-13 Stichting Radboud universitair medisch centrum Antisense oligonucleotides for treatment of usher 2a. exon 68
EP4599060A1 (en) * 2022-10-06 2025-08-13 Stichting Radboud universitair medisch centrum Antisense oligonucleotides for treatment of usher 2a. exons 30-31
WO2024110770A1 (en) * 2022-11-22 2024-05-30 INSERM (Institut National de la Santé et de la Recherche Médicale) A new promoter for retinal pigment epithelium (rpe) targeted gene therapy
EP4634391A2 (en) 2022-12-15 2025-10-22 Empirico Inc. Treatment of mst1 related diseases and disorders
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy
AU2024215901A1 (en) * 2023-01-31 2025-07-24 AcuraStem Incorporated Syf2 antisense oligonucleotides
CN115948561B (zh) * 2023-02-10 2024-01-02 武汉艾米森生命科技有限公司 一种用于食管鳞癌诊断或辅助诊断的试剂、检测试剂盒及其应用
JP2026509436A (ja) * 2023-03-06 2026-03-19 ラクティゲン セラピューティクス 第vii因子発現を活性化するオリゴヌクレオチド調節因子およびその血友病治療への使用
CN116173058B (zh) * 2023-03-08 2025-03-14 天津医科大学第二医院 一种bp-pei@rna纳米药物复合体、制备方法及其在治疗癌症中的应用
WO2024206668A1 (en) * 2023-03-31 2024-10-03 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic strategy for pcdh19-related encephalopathy
WO2024215825A1 (en) * 2023-04-14 2024-10-17 Avicenna Biotech Research, Llc Rna-based compositions and methods for treating breast cancer
WO2024229292A2 (en) * 2023-05-02 2024-11-07 Duke University Compositions and methods for engineering mature ipsc-derived and esc-derived hepatocytes
CN117165672B (zh) * 2023-08-31 2025-04-01 重庆医科大学 Mov10作为新靶点在糖尿病肾病诊断和治疗药物中的应用
JP2025531956A (ja) * 2023-09-01 2025-09-29 フォリア インターナショナル 脱毛症の処置用の経口ミノキシジルに対する経口サプリメントの組成物及び方法
KR20250064736A (ko) * 2023-11-02 2025-05-12 (주)지노믹트리 방광암 예방 또는 치료용 조성물
WO2025101979A1 (en) * 2023-11-08 2025-05-15 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of genes for treatment of non-alcoholic steatohepatitis or metabolic dysfunction-associated steatohepatitis
WO2025111565A1 (en) * 2023-11-22 2025-05-30 Empirico Inc. Treatment of sos2 related diseases and disorders
WO2025155772A1 (en) * 2024-01-19 2025-07-24 Gene Company (Pty)Ltd. Alpha-1 anti-trypsin upregulating polynucleotides and method of use and treatment thereof
WO2025159427A1 (ko) * 2024-01-26 2025-07-31 서울대학교산학협력단 신규한 apoe 안티센스 올리고뉴클레오타이드 및 이의 용도
EP4671372A3 (en) 2024-01-29 2026-03-11 Arnatar Therapeutics, Inc Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
WO2025171086A1 (en) * 2024-02-07 2025-08-14 Asimov Inc. Promoters and uses thereof
US12417220B2 (en) * 2024-02-22 2025-09-16 Sap Se Generative data modeling using large language model
WO2025207750A1 (en) * 2024-03-26 2025-10-02 N-Lorem Foundation Kif1a-targeted oligomeric compounds and uses thereof
WO2025207784A1 (en) * 2024-03-26 2025-10-02 The Children's Medical Center Corporation Slc6a1 gene therapy constructs
WO2025222056A1 (en) * 2024-04-19 2025-10-23 Empirico Inc. Treatment of cdhr3 related diseases and disorders
WO2025224036A1 (en) 2024-04-22 2025-10-30 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
WO2025231449A1 (en) * 2024-05-02 2025-11-06 Institute For Myeloma & Bone Cancer Research Prediction, diagnosis, and treatment of multiple myeloma
WO2025231528A1 (en) * 2024-05-09 2025-11-13 Baker Heart and Diabetes Institute Compositions and methods for treating fibrosis
WO2025240499A1 (en) * 2024-05-15 2025-11-20 Empirico Inc. Treatment of plod2 related diseases and disorders
CN118717788A (zh) * 2024-07-10 2024-10-01 广东医科大学附属医院 一种lncRNA在制备结肠癌药物中的应用
WO2026027887A2 (en) * 2024-08-02 2026-02-05 Mina Therapeutics Limited Hbg1/2-sarna compositions and methods of use
CN119780433B (zh) * 2024-12-13 2025-07-29 首都医科大学附属北京友谊医院 一种以otud7b为靶点在制备诊断和/或防治主动脉夹层产品中的应用
CN121249659A (zh) * 2025-04-07 2026-01-02 首都医科大学附属北京儿童医院 一种靶向PRMT3抑制HIV-1复制、转录再激活的siRNA
CN120771286A (zh) * 2025-07-18 2025-10-14 首都医科大学宣武医院 Nsun3在促进周围神经损伤修复中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1255550A (zh) * 1998-11-30 2000-06-07 张良平 一种新的抗异种移植抗原位点合成酶反义基因克隆
WO2004044123A2 (en) * 2002-11-14 2004-05-27 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
JP2008538896A (ja) * 2005-04-15 2008-11-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 小分子活性化rna分子及び使用方法
JP2013532973A (ja) * 2010-06-23 2013-08-22 ミナ セラピューティクス リミテッド Rna分子およびその使用
JP2014501492A (ja) * 2010-10-08 2014-01-23 ミナ セラピューティクス リミテッド 短いrna分子

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
JP5141256B2 (ja) 2005-10-20 2013-02-13 旭硝子株式会社 ポリテトラフルオロエチレン水性分散液およびその製品
WO2007086990A2 (en) 2005-11-17 2007-08-02 Board Of Regents, The University Of Texas System Modulation of gene expression by oligomers targeted to chromosomal dna
JP5713377B2 (ja) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート 薬物標的としての天然アンチセンスおよび非コードrna転写物
US8178503B2 (en) * 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
US7901882B2 (en) * 2006-03-31 2011-03-08 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
RU2619185C2 (ru) * 2009-12-23 2017-05-12 Курна, Инк. Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
CA2817256A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
US9164590B2 (en) * 2010-12-24 2015-10-20 Kevadiya, Inc. System and method for automated capture and compaction of instructional performances
US11293064B2 (en) * 2013-05-02 2022-04-05 Thomas Jefferson University Human miRNAs for use in diagnosis, prognosis, and therapy of human conditions and diseases
WO2023099884A1 (en) * 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1255550A (zh) * 1998-11-30 2000-06-07 张良平 一种新的抗异种移植抗原位点合成酶反义基因克隆
WO2004044123A2 (en) * 2002-11-14 2004-05-27 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
JP2008538896A (ja) * 2005-04-15 2008-11-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 小分子活性化rna分子及び使用方法
JP2013532973A (ja) * 2010-06-23 2013-08-22 ミナ セラピューティクス リミテッド Rna分子およびその使用
JP2014501492A (ja) * 2010-10-08 2014-01-23 ミナ セラピューティクス リミテッド 短いrna分子

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108753967B (zh) * 2018-06-08 2022-06-17 复旦大学附属中山医院 一种用于肝癌检测的基因集及其panel检测设计方法
CN108753967A (zh) * 2018-06-08 2018-11-06 复旦大学附属中山医院 一种用于肝癌检测的基因集及其panel检测设计方法
CN109097466A (zh) * 2018-09-21 2018-12-28 王赞鑫 与主动脉夹层疾病相关的snp位点及其应用
KR102806666B1 (ko) 2018-10-30 2025-05-12 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 샘플 품질 평가 방법
KR20210089178A (ko) * 2018-10-30 2021-07-15 소마로직, 인크. 샘플 품질 평가 방법
CN109207585A (zh) * 2018-11-01 2019-01-15 中国人民解放军第Oo医院 免疫性血小板减少症lncRNA标志物及试剂盒和应用
JP7241185B2 (ja) 2019-01-17 2023-03-16 エフ. ホフマン-ラ ロシュ アーゲー E3ユビキチンリガーゼ(ube3a)のタンパク質標的
JP2022517803A (ja) * 2019-01-17 2022-03-10 エフ.ホフマン-ラ ロシュ アーゲー E3ユビキチンリガーゼ(ube3a)のタンパク質標的
CN110184358A (zh) * 2019-06-25 2019-08-30 台州市立医院 甲状腺癌早期诊断用的oit3基因及其应用
JP2022552940A (ja) * 2019-09-20 2022-12-21 ラクティゲン セラピューティクス 血小板減少症を治療するための核酸分子及びその応用
JP2023514292A (ja) * 2020-02-14 2023-04-05 カーディオミックス エス.アール.エル. ブルガダ症候群の診断のためのバイオマーカーセット
JP2023550697A (ja) * 2020-10-30 2023-12-05 ▲復▼旦大学 免疫応答調節または抗腫瘍のための薬剤の調製におけるitpripl1のモジュレーターとしての使用
JP2024500823A (ja) * 2020-12-23 2024-01-10 イーライ リリー アンド カンパニー Rna治療薬及びその使用方法
JP2025148338A (ja) * 2020-12-23 2025-10-07 イーライ リリー アンド カンパニー Rna治療薬及びその使用方法
JP7756166B2 (ja) 2020-12-23 2025-10-17 イーライ リリー アンド カンパニー Rna治療薬及びその使用方法
JP2024543933A (ja) * 2022-01-14 2024-11-26 タスリー・ステム・セル・バイオロジー・ラボラトリー・タスリー・グループ・リミテッド 間葉系間質細胞品質評価方法
JP7795630B2 (ja) 2022-01-14 2026-01-07 タスリー・ステム・セル・バイオロジー・ラボラトリー・タスリー・グループ・リミテッド 間葉系間質細胞品質評価方法
WO2024005158A1 (ja) * 2022-06-30 2024-01-04 武田薬品工業株式会社 オリゴヌクレオチド

Also Published As

Publication number Publication date
US20210363525A1 (en) 2021-11-25
WO2016170348A8 (en) 2017-11-30
WO2016170348A3 (en) 2017-04-13
US20180305689A1 (en) 2018-10-25
JP2021035360A (ja) 2021-03-04
EP3286318A2 (en) 2018-02-28
WO2016170348A2 (en) 2016-10-27
JP2023040138A (ja) 2023-03-22

Similar Documents

Publication Publication Date Title
US20210363525A1 (en) Sarna compositions and methods of use
US12006329B2 (en) Protein degraders and uses thereof
US11932635B2 (en) CRBN ligands and uses thereof
US20250084141A1 (en) Rna encoding a therapeutic protein
US20240165239A1 (en) Covalent Binding Compounds for the Treatment of Disease
US12281301B2 (en) Sequencing-based proteomics
AU2018338314B2 (en) Protein degraders and uses thereof
JP2018512876A6 (ja) saRNA組成物および使用方法
US20230193205A1 (en) Gene modified fibroblasts for therapeutic applications
US20220401460A1 (en) Modulating resistance to bcl-2 inhibitors
US20230093080A1 (en) Protein degraders and uses thereof
JP2025172749A (ja) 修飾タンパク質および関連の処置方法
US12054756B2 (en) Engineered nucleases, compositions, and methods of use thereof
US20250388634A1 (en) Engineered gene effectors, compositions, and methods of use thereof
US20260085300A1 (en) Systems and compositions for fusion polypeptides and methods of use thereof
CN121532411A (zh) 用于调控靶基因的系统和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200526

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201222